谷歌浏览器插件
订阅小程序
在清言上使用

A commentary on drug safety and genomics: Promising new agents may require expansion of guidelines for subject screening in clinical trials

Toxicology Research and Application(2021)

引用 0|浏览0
暂无评分
摘要
The fatty acid amide hydrolase (FAAH) inhibitors likely represent a novel therapeutic yet complex target with the potential to impact various disease processes that present significant unmet medical needs. Despite a history of significant adverse events and still ill-defined risks associated with FAAH inactivation, potential clinical results of FAAH inhibitors for the management of human diseases suggest strongly that the research not be abandoned. In the present commentary we argue that the way to move forward safely and effectively may lie in universal expansion of clinical trials guidelines and toxicology protocols to include targeted genomic screening of clinical trial subjects. Generalization to the safety testing of many new pharmaceutical agents may be the silver lining of an otherwise dark cloud.
更多
查看译文
关键词
drug safety,clinical trials,subject screening,genomics
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要